Audentes Therapeutics (BOLD) Given “Buy” Rating at Cowen

Cowen reiterated their buy rating on shares of Audentes Therapeutics (NASDAQ:BOLD) in a report published on Friday, March 9th.

BOLD has been the subject of several other research reports. HC Wainwright set a $37.00 price objective on shares of Audentes Therapeutics and gave the company a buy rating in a research note on Friday, March 9th. Zacks Investment Research raised shares of Audentes Therapeutics from a hold rating to a buy rating and set a $37.00 price objective for the company in a research note on Thursday, March 8th. William Blair reaffirmed a buy rating on shares of Audentes Therapeutics in a research note on Friday, January 5th. ValuEngine cut shares of Audentes Therapeutics from a hold rating to a sell rating in a research note on Friday, December 1st. Finally, BMO Capital Markets set a $44.00 price objective on shares of Audentes Therapeutics and gave the company a buy rating in a research note on Friday, January 5th. One analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the company. Audentes Therapeutics presently has a consensus rating of Buy and an average price target of $35.56.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ BOLD traded down $1.42 during midday trading on Friday, hitting $28.63. The company’s stock had a trading volume of 387,652 shares, compared to its average volume of 443,573. Audentes Therapeutics has a one year low of $13.90 and a one year high of $41.80.

Audentes Therapeutics (NASDAQ:BOLD) last issued its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.09. research analysts predict that Audentes Therapeutics will post -3.43 earnings per share for the current fiscal year.

In other news, VP Suyash Prasad sold 7,800 shares of the company’s stock in a transaction on Thursday, March 29th. The shares were sold at an average price of $30.03, for a total value of $234,234.00. Following the completion of the sale, the vice president now owns 7,800 shares of the company’s stock, valued at approximately $234,234. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Orbimed Advisors Llc sold 421,638 shares of the company’s stock in a transaction on Friday, March 2nd. The shares were sold at an average price of $35.17, for a total transaction of $14,829,008.46. The disclosure for this sale can be found here. In the last three months, insiders sold 1,127,407 shares of company stock valued at $39,177,415. Corporate insiders own 47.30% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Perceptive Advisors LLC boosted its stake in shares of Audentes Therapeutics by 10.4% in the 3rd quarter. Perceptive Advisors LLC now owns 781,309 shares of the biotechnology company’s stock valued at $21,885,000 after purchasing an additional 73,809 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in Audentes Therapeutics by 35.1% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 34,597 shares of the biotechnology company’s stock valued at $1,082,000 after buying an additional 8,997 shares during the last quarter. Mckinley Capital Management LLC Delaware bought a new stake in Audentes Therapeutics during the 3rd quarter valued at $1,333,000. Victory Capital Management Inc. raised its holdings in Audentes Therapeutics by 23.2% during the 4th quarter. Victory Capital Management Inc. now owns 87,674 shares of the biotechnology company’s stock valued at $2,740,000 after buying an additional 16,500 shares during the last quarter. Finally, Farallon Capital Management LLC bought a new stake in Audentes Therapeutics during the 4th quarter valued at $9,989,000. 66.96% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Enterprise Leader and is the sole property of of Enterprise Leader. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://theenterpriseleader.com/2018/04/02/audentes-therapeutics-bold-buy-rating-reaffirmed-at-cowen.html.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply